alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 851–875 of 2,047 studies published 2026 (page 35 of 82) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Cost-effectiveness of a music therapy intervention for people living with dementia: a model for a UK-based economic evaluation

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Aging & Mental Health 2026-03-04

Over a three-month period, MT+CST was more effective than CST alone in improving cognitive function but was not cost-effective due to higher initial costs, including setup and equipment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Elucidation of Molecular Mechanisms of Lipid-Altered Cytotoxicity of TDP-43 Fibrils

✓ Peer-reviewed alzhub usefulness score 38 out of 100. ACS Chemical Neuroscience 2026-01-29

Progressive aggregation of TAR DNA-binding protein 43 (TDP-43) is a hallmark of numerous neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, and limbic predominant age-related TDP-43 encephalopathy (LATE). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Small molecule JRMS modulating importin-β1 chaperone activity as a therapeutic strategy reducing TDP-43 pathology

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neurotherapeutics 2026-01-01

Neuronal cytoplasmic aggregation and nuclear depletion of the TAR DNA-binding protein 43 (TDP-43) is the most characteristic pathology of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), causing toxicity through cytoplasmic gain and nuclear loss of function mechanisms. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multi-Dimensional Transcriptomics Reveals the Prominent Role of Neuroinflammation in Alzheimer’s Disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. International Journal of Molecular Sciences 2026-06-02

Alzheimer's Disease (AD), the most common form of dementia, is pathologically defined by extracellular beta-amyloid (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs), accompanied by chronic neuroinflammation. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Distinct and combined interferon-ɑ/β-receptor-1 loss in neurons and astrocytes disrupt brain energy metabolism and drive Parkinsonian dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Biomedical Science 2026-06-01

IFNAR1 plays a crucial role in brain and mitochondrial homeostasis, loss of which results in neurodegeneration and neuropathology resembling PDD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Synaptic loss in alcohol use disorder: clinical and mechanistic insights from a PET imaging study

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Clinical Investigation 2026-03-31

Alcohol use disorder (AUD) is linked with changes in brain structure and function, with robust evidence for neurodegenerative changes, including synaptic loss in preclinical models. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Clinicopathological features of primary tauopathies: a brain bank series

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Neurology 2026-03-30

Fifteen cases were identified, spanning argyrophilic grain disease, primary age-related tauopathy, corticobasal degeneration, genetic frontotemporal dementia, and progressive supranuclear palsy. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cinnamon Bud Extract Is a Source of Biomolecules Active against the Aggregation and Condensation of Alzheimer′s-Associated Tau Protein

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Agricultural and Food Chemistry 2026-04-02

High Resolution Image Download MS PowerPoint Slide Abnormal accumulation of tau fibrillar aggregates is a hallmark of tauopathies, including Alzheimer’s disease. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Overcoming the blood–brain barrier in Alzheimer's disease: translational perspectives on advanced drug delivery platforms

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Neuroscience 2026-05-14

Alzheimer's disease (AD) is the leading cause of dementia worldwide and represents a growing public health challenge in aging societies. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MIND diet moderates the associations between cerebrovascular and neurodegenerative disease burden and cognition

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Frontiers in Nutrition 2026-05-13

The MIND diet may buffer the cognitive consequences of cerebrovascular pathology and cortical atrophy in older adults at elevated dementia risk and promote cognitive resilience over general healthy eating guidelines. 2 key findings →

Design: post-hoc analysis Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effects of Dementia on Adverse Outcomes in Geriatric Patients Undergoing Elective Total Hip Arthroplasty: Analysis of the US Nationwide Inpatient Sample

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Geriatric Orthopaedic Surgery & Rehabilitation 2026-01-16

376 323 elective geriatric THA patient samples from the NIS database were included, with an overall dementia prevalence of 2.05%. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Microglial reactivity predicts hippocampal, but not global, atrophy in cerebral small vessel disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2026-04-01

Our data suggests that microglial reactivity may play a role in hippocampal atrophy; potentially contributing to the increasingly recognized interaction between vascular and neurodegenerative pathology. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis

✓ Peer-reviewed alzhub usefulness score 38 out of 100. JAR life 2026-06-17

Anti-amyloid monoclonal antibodies (lecanemab and donanemab) represent the first disease-modifying therapies for early symptomatic Alzheimer's disease (AD)- Italy's National Health Service (SSN) must determine whether to include these therapies within Essential Levels of Care (LEA), requiring reimbursement across all regions. 5 key findings →

Participants: 42,000 Evidence: low

Full summary, score breakdown and related studies → Original source

Clinical meaningfulness of anti-amyloid therapies in early Alzheimer's disease: Perspectives from the East and Southeast Asia region

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-02-23

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive accumulation of toxic amyloid species. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Neighborhood Socioeconomic Deprivation is Associated with Worse Cognitive Performance and in vivo Amyloid Accumulation

✓ Peer-reviewed alzhub usefulness score 38 out of 100. NPJ dementia 2026-02-12

Socioeconomic disadvantage (SED) has been associated with poorer brain health, yet its underlying pathology remains incompletely understood. 5 key findings →

Participants: 1,110 Evidence: low

Full summary, score breakdown and related studies → Original source

The social value of lecanemab for patients with early Alzheimer's disease in Japan

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Journal of Alzheimer's Disease 2026-05-10

BackgroundLecanemab is the first approved disease-modified therapy in Japan for patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia (AD-D).ObjectiveThis study aims to evaluate the social value of lecanemab in Japan. 1 key finding →

Design: modelling Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Lecanemab use for early Alzheimer disease in Canada

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Canadian Medical Association Journal 2026-06-28

Lecanemab is a humanized monoclonal antibody that binds soluble brain amyloid-β protein, promoting its removal and slowing the underlying process of Alzheimer disease. 1 This mechanism aligns with the amyloid hypothesis, a debated model of Alzheimer disease pathogenesis.1 Only patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease are eligible for lecanemab treatment. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed